Alpha Synuclein Market Is Likely to Experience a Tremendous Growth by 2029
Alpha-synuclein
market is anticipated to grow at a significant CAGR during the forecast
period. Alpha-synuclein is a neuronal protein that is encoded by the SNCA gene
in humans and is abundant in the brain, while smaller amounts of it are found
in the heart, muscle, and other tissues. Alpha-synuclein is a protein that
regulates synaptic vesicle trafficking and subsequent neurotransmitter release.
Abnormal alpha-synuclein depositions (?-synucleinopathies) in neurons, nerve
fibers, or glia cells are the causes for several neurodegenerative diseases
such as Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple
system atrophy (MSA). Parkinson’s disease is the most common progressive
neurodegenerative movement disorder with significant prevalence and incidences
across the globe.
Increasing prevalence and incidences of Parkinson’s
disease globally is one of the major factors that is augmenting the growth of
the global alpha-synuclein market. A significant increase in the number of Parkinson’s
disease patients along with the limited treatment solutions for this disease
serves as a potential growth factor for the market globally. Furthermore,
industry players are aggressively focusing on the development of treatment
solutions for Parkinson’s disease through alpha-synuclein which is further
boosting the market growth. For instance, Roche presented its monoclonal
antibody (mAb)-targeting alpha (?)-synuclein, prasinezumab, for the treatment
of Parkinson’s disease at the 15th International Virtual Conference on
Alzheimer’s disease and Parkinson’s disease (AD/PD) 2021. Prasinezumab is an
?-synuclein mAb administered intravenously as an infusion.
Some key players operating in the market include F.
Hoffmann La-Roche AG, and H. Lundbeck A/S, among others. These players are
eyeing on strengthening their position in the market by adopting various
strategies such as mergers and acquisitions, partnerships and collaborations,
new product launches, development in the existing product portfolio, and so on.
To Request a Sample of our Report on Alpha Synuclein
Market: https://www.omrglobal.com/request-sample/alpha-synuclein-market
Market Coverage
·
The market number available for – 2022-2030
·
Base year- 2022
·
Forecast period- 2023-2030
Segment Covered-
·
By Type
·
By Application
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape: F. Hoffmann La-Roche AG, and H. Lundbeck A/S,
among others.
A
full Report of Alpha Synuclein Market is
Available @ https://www.omrglobal.com/industry-reports/alpha-synuclein-market
Alpha Synuclein Market Report by Segment
By Type
·
AV-1950R
·
AV-1947D
·
BAN-0805
·
BIIB-054
·
DPC-003
·
Others
By Application
·
Multiple System Atrophy
·
Neurodegenerative Disease
·
Lewy Body Dementia
·
Others
Alpha Synuclein Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and
consulting company known for its crisp and concise reports. The company is
equipped with an experienced team of analysts and consultants. OMR offers
quality syndicated research reports, customized research reports, consulting
and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting
Services through another subsidiary Encanto
Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment